Linker Information
General Information of This Linker
| Linker ID |
LIN0BPCGI
|
|||||
|---|---|---|---|---|---|---|
| Linker Name |
Mal-Asp-Val
|
|||||
| Linker Type |
Cathepsin-cleavable linker
|
|||||
| Antibody-Linker Relation |
Cleavable
|
|||||
| Structure |
|
|||||
| Formula |
C18H27N5O7
|
|||||
| Isosmiles |
CC(C)C(N)C(=O)NC(CC(=O)O)C(=O)NCCNC(=O)CCN1C(=O)C=CC1=O
|
|||||
| InChI |
InChI=1S/C18H27N5O7/c1-10(2)16(19)18(30)22-11(9-15(27)28)17(29)21-7-6-20-12(24)5-8-23-13(25)3-4-14(23)26/h3-4,10-11,16H,5-9,19H2,1-2H3,(H,20,24)(H,21,29)(H,22,30)(H,27,28)
|
|||||
| InChIKey |
BBXGVNLYYLAPGD-UHFFFAOYSA-N
|
|||||
| Pharmaceutical Properties |
Molecule Weight
|
425.442
|
Polar area
|
188
|
||
|
Complexity
|
30
|
xlogp Value
|
-2.5233
|
|||
|
Heavy Count
|
30
|
Rot Bonds
|
12
|
|||
|
Hbond acc
|
7
|
Hbond Donor
|
5
|
|||
Each Antibody-drug Conjugate Related to This Linker
Full Information of The Activity Data of The ADC(s) Related to This Linker
1F6-Asp-Val-AF [Investigative]
Revealed Based on the Cell Line Data
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal Inhibitory Concentration (IC50) |
8.00 ng/mL
|
Positive CD70 expression (CD70+++/++) | ||
| Method Description |
IC50 values are the mean and SD of 21 independent experimental titrations, each performed at least in duplicate.
|
||||
| In Vitro Model | Clear cell renal cell carcinoma | Caki-1 cells | CVCL_0234 | ||
| Experiment 2 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal Inhibitory Concentration (IC50) |
8.00 ng/mL
|
Positive CD70 expression (CD70+++/++) | ||
| Method Description |
IC50 values are the mean and SD of 21 independent experimental titrations, each performed at least in duplicate.
|
||||
| In Vitro Model | Hodgkin lymphoma | L-428 cells | CVCL_1361 | ||
| Experiment 3 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal Inhibitory Concentration (IC50) |
9.00 ng/mL
|
Positive CD70 expression (CD70+++/++) | ||
| Method Description |
IC50 values are the mean and SD of 21 independent experimental titrations, each performed at least in duplicate.
|
||||
| In Vitro Model | Renal cell carcinoma | 786-O cells | CVCL_1051 | ||
| Experiment 4 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal Inhibitory Concentration (IC50) |
18.00 ng/mL
|
Positive CD70 expression (CD70+++/++) | ||
| Method Description |
IC50 values are the mean and SD of 21 independent experimental titrations, each performed at least in duplicate.
|
||||
| In Vitro Model | Renal cell carcinoma | 786-O cells | CVCL_1051 | ||
| Experiment 5 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal Inhibitory Concentration (IC50) |
18.00 ng/mL
|
Positive CD70 expression (CD70+++/++) | ||
| Method Description |
IC50 values are the mean and SD of 21 independent experimental titrations, each performed at least in duplicate.
|
||||
| In Vitro Model | Hodgkin lymphoma | L-428 cells | CVCL_1361 | ||
| Experiment 6 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal Inhibitory Concentration (IC50) |
25.00 ng/mL
|
Positive CD70 expression (CD70+++/++) | ||
| Method Description |
IC50 values are the mean and SD of 21 independent experimental titrations, each performed at least in duplicate.
|
||||
| In Vitro Model | Clear cell renal cell carcinoma | Caki-1 cells | CVCL_0234 | ||
If you find any error in data or bug in web service, please kindly report it to Dr. Shen et al.